In a Bloomberg feature on private equity-backed companies returning to the public markets, IPOX® Founder Josef Schuster provided key insights. He explained that these offerings are "usually more efficiently priced than other IPOs, so we don’t expect to see a significant pop initially," despite a wide-open IPO window.

In a new report, Zacks Investment Research highlights two IPOX®-based ETFs (FPX, FPXI) as prime ways to access the recovering IPO market. Citing a sharp rebound in new listings and strong investor sentiment, the analysis points to significant growth opportunities. Our flagship U.S. and International indexes provide the basis for these featured funds.

In a Reuters article on Ambiq Micro's U.S. IPO filing, IPOX® Research Associate Lukas Muehlbauer provided analysis on the company’s plans. He noted the chip designer's customer concentration risk but also highlighted its competitive advantage in the wearables market by targeting the "AI at the edge" niche with its ultra-low-power chips.

In a recent Bloomberg article, IPOX® Research Associate Lukas Muehlbauer commented on the significant rights issuance planned by Saudi Arabia's ACWA Power Co. The utility company is set to undertake the Middle East's largest such deal since 2023, aiming to raise $1.9 billion to fund its strategic expansion.

In a Reuters article covering the strong market debut of Jefferson Capital, IPOX® Research Associate Lukas Muehlbauer provided commentary on the recovering U.S. IPO market. He noted the rebound is likely to be selective, "led by high-quality and long-anticipated issuers." Muehlbauer explained that an initial trading "pop" is part of the market's "healthy process of price discovery" to establish a sustainable price. Read more in the full article on the IPOX website.

In a recent Bloomberg article, IPOX® Research Associate Lukas Muehlbauer commented on the challenging European IPO market. Highlighting the recent withdrawal of several listings, Muehlbauer noted that investor appetite is particularly low for private equity exits where proceeds do not benefit the company. He stated, “Deals that are essentially existing owners cashing out are proving to be a tough sell.” Read more about his analysis of the current market sentiment on our blog.

The IPOX® 100 U.S. Index (ETF: FPX) is opening at a new all-time high, extending its year-to-date gain to +21%. This surge is driven by positive market sentiment, end-of-quarter positioning, and reassuring inflation comments from the FED. Other key indexes, including the IPOX® International (FPXI) and IPOX® 100 Europe (FPXE), also closed at multi-year highs, reflecting broad strength across the IPOX® portfolio and its position as the gold standard for IPOs.

IPOX® Research Associate Lukas Muehlbauer commented on the news of Wealthfront Corporation's confidential U.S. IPO filing in a Reuters article on June 23, 2025. He noted that the move is consistent with a recent positive trend in the market, stating, "Wealthfront's IPO plans fit in with the recent uptick of successful U.S. IPOs, particularly from sectors insulated from trade and supply chain volatility."

In a Reuters article on Slide Insurance's $2.6 billion IPO, IPOX® Vice President Kat Liu provided expert insights. Liu commented on the firm's niche strategy in high-risk coastal markets and the appeal of insurer IPOs due to predictable cash flows. She also offered perspective on potential governance concerns at the newly public company, highlighting IPOX's expertise in analyzing new listings and market trends in the global financial sector.

In a recent Bloomberg feature, IPOX® Founder and CEO Josef Schuster analyzed the potential IPO of Vale SA’s base metals unit. He noted a listing based on its $25 billion valuation could be the most valuable mining stock debut since Glencore Plc in 2011, stating it “would definitely rank amongst the top 10 mining IPOs.” This commentary underscores the historic scale of the potential offering in the global materials sector. Read more here.

IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary for Bloomberg News on the volatile debut of Saudi Arabian low-cost carrier Flynas and the company's resilience in the face of increased regional instability.

IPOX® Research Associate Dr. Lukas Muehlbauer commented on the U.S. IPO filing of Australian meat producer Kilcoy Global Foods. The article discusses the recent resurgence in the U.S. IPO market and notes that Kilcoy's listing will be a significant indicator of investor appetite for companies with intricate global supply chains.

In a Reuters article covering Chime’s IPO, IPOX® VP Kat Liu, provided expert commentary on the implications of the company’s strong market reception. Ms. Liu noted that the performance of a high-profile "unicorn" like Chime is being closely watched and could encourage other private fintech companies to move forward with their own public offerings.

In a Reuters article covering the successful market debut of Voyager Technologies, IPOX® Associate Lukas Muehlbauer was quoted in the piece, stating, "Strategic government backing amid increased defense spending somewhat shields these [defense] firms from tariff-induced supply chain risks." His analysis underscores the unique factors contributing to the resilience and attractiveness of companies within the sector.

In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's recent surge in performance. He described a "positive feedback loop" where unsatisfied demand for one hot listing is driving investor orders for the next, contributing to the market's momentum. Schuster noted that while this enthusiasm is promising, the true test for the recovery will be the fundamental strength shown in the first quarterly earnings from these newly public companies, stating, "When you see the first set of earnings from some of these companies, you will really see how substantial this recovery of the IPO market is going to be."

In a recent Reuters article, IPOX® VP Kat Liu, provided commentary on the upcoming IPO of property insurance technology company Slide. The company is reportedly targeting a valuation of up to $2.12 billion and aims to raise as much as $340 million.

In a recent report by Reuters, IPOX® Research Associate Dr. Lukas Muehlbauer provided commentary on the upcoming U.S. initial public offering of cancer diagnostic firm Caris Life Sciences. The company is aiming for a valuation of up to $5.3 billion, seeking to raise as much as $423.5 million.

In a Reuters report on Circle's successful market debut, IPOX® Research Associate Lukas Muehlbauer offered context on the strengthening IPO pipeline. He observed that the most successful recent listings have been from firms in resilient industries, stating they were "largely by companies less exposed to international supply chain risks" and that the trend would likely continue for sectors such as AI, defense, or fintech.

In a Reuters feature on Gemini's recent IPO filing, IPOX® Vice President Kat Liu commented on the growing trend of digital asset firms going public. Liu explained that this move signals a readiness from long-anticipated firms to re-engage with public capital. She noted, "investor appetite is returning, especially for companies with well-defined business models in strategic sectors such as fintech, AI and digital assets," highlighting the renewed market vigor for such offerings.

In a recent Bloomberg article, IPOX® Founder Josef Schuster provided his expert commentary on the U.S. IPO market's striking resilience despite recent volatility. He noted the market's ability to withstand bond market pressures, highlighting that strong performers like CoreWeave are boosting investor confidence. Schuster observed that "risk appetite is rising for certain deals," indicating potential for continued positive momentum given solid company fundamentals and performance.